{
    "info": {
        "nct_id": "NCT03383575",
        "official_title": "Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome",
        "inclusion_criteria": "* Signed, informed consent must be obtained prior to any study specific procedures\n* Subjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO), and chronic myelomonocytic leukemia (CMML) are eligible\n* Subjects must have an IDH2 gene mutation (IDH2-R140 or R172) as determined by local laboratory result\n* (Arm A only): Subject must be hypomethylating agent naive (i.e. prior azacitidine, decitabine, SGI-110 is exclusionary). Receipt of other MDS-directed therapy such as lenalidomide is allowed\n* (Arm A only): Subjects with high-risk MDS (i.e. International Prostate Symptom Score [IPSS] intermediate-2 or high-risk; or revised [R]-IPSS high or very-high risk). Patients with intermediate-1 risk by IPSS or intermediate risk by R-IPSS with high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible\n* (Arm B only): Subject must be relapsed or refractory to prior hypomethylating agent therapy, defined as prior receipt of 6 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Serum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease)\n* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN\n* Serum creatinine =< 2 x the ULN\n* Able to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements\n* Resolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatment\n* Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "* Any prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study\n* Subject has received a prior targeted IDH2 inhibitor\n* Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures\n* Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection\n* Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy\n* Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement\n* Impaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months\n* Subjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline\n* Nursing or pregnant women\n* Subjects with known hypersensitivity to study drugs or their excipients",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed, informed consent must be obtained prior to any study specific procedures",
            "criterions": [
                {
                    "exact_snippets": "Signed, informed consent must be obtained",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to any study specific procedures",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "before study specific procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO), and chronic myelomonocytic leukemia (CMML) are eligible",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed diagnosis of MDS",
                    "criterion": "myelodysplastic syndrome (MDS) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histology"
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory anemia with excess blasts in transformation (RAEB-T)",
                    "criterion": "refractory anemia with excess blasts in transformation (RAEB-T) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria",
                    "criterion": "acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "blast percentage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 20,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "%"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dysplasia",
                            "expected_value": "multilineage"
                        },
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "French-American-British (FAB)"
                        }
                    ]
                },
                {
                    "exact_snippets": "by World Health Organization (WHO)",
                    "criterion": "diagnostic criteria (WHO)",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic myelomonocytic leukemia (CMML)",
                    "criterion": "chronic myelomonocytic leukemia (CMML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Arm A only): Subject must be hypomethylating agent naive (i.e. prior azacitidine, decitabine, SGI-110 is exclusionary). Receipt of other MDS-directed therapy such as lenalidomide is allowed",
            "criterions": [
                {
                    "exact_snippets": "Subject must be hypomethylating agent naive (i.e. prior azacitidine, decitabine, SGI-110 is exclusionary)",
                    "criterion": "prior exposure to hypomethylating agents",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Receipt of other MDS-directed therapy such as lenalidomide is allowed",
                    "criterion": "prior exposure to other MDS-directed therapy (e.g., lenalidomide)",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Arm A only): Subjects with high-risk MDS (i.e. International Prostate Symptom Score [IPSS] intermediate-2 or high-risk; or revised [R]-IPSS high or very-high risk). Patients with intermediate-1 risk by IPSS or intermediate risk by R-IPSS with high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible",
            "criterions": [
                {
                    "exact_snippets": "Subjects with high-risk MDS (i.e. International Prostate Symptom Score [IPSS] intermediate-2 or high-risk; or revised [R]-IPSS high or very-high risk)",
                    "criterion": "myelodysplastic syndrome (MDS) risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category (IPSS)",
                            "expected_value": [
                                "intermediate-2",
                                "high"
                            ]
                        },
                        {
                            "requirement_type": "risk category (R-IPSS)",
                            "expected_value": [
                                "high",
                                "very-high"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with intermediate-1 risk by IPSS or intermediate risk by R-IPSS with high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations",
                    "criterion": "myelodysplastic syndrome (MDS) risk category with high-risk molecular features",
                    "requirements": [
                        {
                            "requirement_type": "risk category (IPSS)",
                            "expected_value": "intermediate-1"
                        },
                        {
                            "requirement_type": "risk category (R-IPSS)",
                            "expected_value": "intermediate"
                        },
                        {
                            "requirement_type": "molecular features",
                            "expected_value": [
                                "TP53 mutation",
                                "ASXL1 mutation",
                                "EZH2 mutation",
                                "RUNX1 mutation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects must have an IDH2 gene mutation (IDH2-R140 or R172) as determined by local laboratory result",
            "criterions": [
                {
                    "exact_snippets": "Subjects must have an IDH2 gene mutation (IDH2-R140 or R172) as determined by local laboratory result",
                    "criterion": "IDH2 gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "mutation type",
                            "expected_value": [
                                "IDH2-R140",
                                "IDH2-R172"
                            ]
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "local laboratory result"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Arm B only): Subject must be relapsed or refractory to prior hypomethylating agent therapy, defined as prior receipt of 6 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy",
            "criterions": [
                {
                    "exact_snippets": "Subject must be relapsed or refractory to prior hypomethylating agent therapy",
                    "criterion": "response to prior hypomethylating agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prior receipt of 6 cycles of HMA therapy",
                    "criterion": "number of prior HMA therapy cycles",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "failure to attain a response",
                    "criterion": "response to HMA therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "relapse after prior response to HMA therapy",
                    "criterion": "relapse after prior response to HMA therapy",
                    "requirements": [
                        {
                            "requirement_type": "relapse_after_response",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease)",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin =< 2 x the upper limit of normal (ULN)",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for patients with Gilbert's disease",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 2 x the ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 2 x the ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements",
            "criterions": [
                {
                    "exact_snippets": "Able to understand and voluntarily sign a written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to understand",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to voluntarily sign",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with protocol requirements",
                    "criterion": "protocol compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... =< 3 x the laboratory ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... =< 3 x the laboratory ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Resolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Resolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatment",
                    "criterion": "treatment-related, non-hematological toxicities (except alopecia) from any previous cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to the first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum pregnancy test",
                                "urine pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Female patients of childbearing potential ... agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug",
                    "criterion": "contraception use (female, childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "dual methods of contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study and for a minimum of 3 months following the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements",
                    "criterion": "menopausal/sterilization status (female)",
                    "requirements": [
                        {
                            "requirement_type": "menopausal status",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 45,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "year without menses"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": "surgically sterilized"
                        }
                    ]
                },
                {
                    "exact_snippets": "Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential",
                    "criterion": "contraception use (male)",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "effective barrier method of contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study and for a minimum of 3 months following the last dose of study drug"
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": "sexually active with a female of childbearing potential"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study",
            "criterions": [
                {
                    "exact_snippets": "Any prior or coexisting medical condition ... in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study",
                    "criterion": "prior or coexisting medical condition",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "substantially increases risk of study participation as judged by investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing or pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled infection at study enrollment",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "known diagnosis of human immunodeficiency virus",
                    "criterion": "human immunodeficiency virus infection",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic active hepatitis B or C infection",
                    "criterion": "hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": "chronic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline",
            "criterions": [
                {
                    "exact_snippets": "corrected QT (QTc) > 480 ms",
                    "criterion": "corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "QTc > 510 msec for subjects with a bundle branch block at baseline",
                    "criterion": "corrected QT interval (QTc) in subjects with bundle branch block at baseline",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 510,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Impaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months",
            "criterions": [
                {
                    "exact_snippets": "Impaired cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association grade III or IV congestive heart failure",
                    "criterion": "congestive heart failure (NYHA grade)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the last 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with known hypersensitivity to study drugs or their excipients",
            "criterions": [
                {
                    "exact_snippets": "Subjects with known hypersensitivity to study drugs or their excipients",
                    "criterion": "hypersensitivity to study drugs or their excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption",
                    "criterion": "gastrointestinal conditions or disorders",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to interfere with study drug absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including prior gastrectomy",
                    "criterion": "prior gastrectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement",
            "criterions": [
                {
                    "exact_snippets": "known active central nervous system (CNS) disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal involvement",
                    "criterion": "leptomeningeal involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received a prior targeted IDH2 inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Subject has received a prior targeted IDH2 inhibitor",
                    "criterion": "prior targeted IDH2 inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric disorders ... precluding understanding of the informed consent process and/or completion of the necessary study procedures",
                    "criterion": "psychiatric disorders",
                    "requirements": [
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "precludes understanding of the informed consent process and/or completion of the necessary study procedures"
                        }
                    ]
                },
                {
                    "exact_snippets": "altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures",
                    "criterion": "altered mental status",
                    "requirements": [
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "precludes understanding of the informed consent process and/or completion of the necessary study procedures"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}